CA-125 test diagnostic test in Ramdas Peth Nagpur
Book CA-125 test diagnostic test at Dr. Saoji Orthopaedic Clinic And Medilab Pathology Laboratory Ramdas Peth in Nagpur India
Price of CA-125 test diagnostic test at Ramdas Peth Nagpur
cost of CA-125 test at Dr. Saoji Orthopaedic Clinic And Medilab Pathology Laboratory in Ramdas Peth Nagpur India
cost CA-125 test diagnostic center in Ramdas Peth Nagpur india
Get cost of CA-125 test at Dr. Saoji Orthopaedic Clinic And Medilab Pathology Laboratory in Ramdas Peth Nagpur India
CA-125 test in Ramdas Peth Nagpur
CA-125 test cost
CA-125 test cost Ramdas Peth Nagpur
CA-125 test cost in Ramdas Peth Nagpur
CA-125 center in Ramdas Peth Nagpur
what is CA-125 ?
CA-125 near to me Ramdas Peth
CA-125 test cost at Ramdas Peth ?
what is a cost of CA-125 test at Ramdas Peth Nagpur ?
Diagnostic centers for CA-125 test in Nagpur
Diagnostic centers for CA-125 test at Ramdas Peth Nagpur
Where can i get CA-125 test ?
|Clinic Name:||Dr. Saoji Orthopaedic Clinic And Medilab Pathology Laboratory|
|Address :||Sky Orthopaedics,1st Floor, Nikalas Tower, Central Bazar Road,--,Nagpur,Maharashtra, 440010|
|Opening hours :|
|Email address :||firstname.lastname@example.org|
|Door Step Sample Collections:||Available|
Cancer Antigen 125 (CA-125) is a protein that is present on the surface of most, but not all, ovarian cancer cells. This makes the test useful as a tumor marker in specific circumstances. The CA-125 test measures the amount of CA-125 in the blood.
Significantly elevated concentrations of CA-125 may be present in the blood of a woman who has ovarian cancer. Thus the test may be used to monitor the effectiveness of treatment and/or for recurrence of the cancer. However, not all women with ovarian cancer will have elevated CA-125 so the test may not be useful in all cases.
Ovarian cancer is the fifth most common cause of cancer death in women. According to the American Cancer Society (ACS), the lifetime risk of a woman developing ovarian cancer is about 1 in 75 and the lifetime risk of death is 1 in 100. ACS estimates that about 22,000 new cases are diagnosed each year in the U.S. and about 14,000 women die of it.
Currently, less than 20% of ovarian cancers are found in the early stages before they have spread outside the ovary. The primary reason they go undetected is that the symptoms of ovarian cancer are fairly non-specific.
The need for a reliable method for early detection of ovarian cancer among asymptomatic women continues to drive ongoing research. In the meantime, regular physicals, pelvic exams, and an awareness of family history and symptoms are important.
CA-125 is not recommended as a screening test for asymptomatic women because it is non-specific. Small quantities of CA-125 are produced by normal tissues throughout the body and by some other cancers. Levels in the blood may be moderately elevated with a variety of non-cancerous conditions, including menstruation, pregnancy, and pelvic inflammatory disease.
CA 125 Tumor Marker; Cancer Antigen 125.
To monitor treatment for ovarian cancer or to detect recurrence; sometimes to evaluate a lump located in the pelvic area (pelvic mass); not recommended for screening asymptomatic women but sometimes ordered to help detect early ovarian cancer in those identified as being at high risk. Before starting therapy for ovarian cancer and at intervals during and after treatment; sometimes when you have a pelvic mass or are at a high risk for developing ovarian cancer.
The CA-125 test may be ordered before a woman starts ovarian cancer treatment as a baseline to compare against future measurements. During therapy, a healthcare practitioner may order CA-125 testing at intervals to monitor response to therapy. CA-125 may also be measured periodically after therapy is completed.
In some cases, a healthcare practitioner may order a CA-125 test when a woman has a pelvic mass in order to help determine the cause.
Some healthcare providers may order a CA-125 test and a transvaginal ultrasound at regular intervals when a woman is at high risk of developing ovarian cancer.